Literature DB >> 29249291

A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.

Todd M Morgan1, Rohit Mehra2, Placede Tiemeny3, J Stuart Wolf4, Shulin Wu5, Zaina Sangale3, Michael Brawer3, Steven Stone3, Chin-Lee Wu5, Adam S Feldman6.   

Abstract

BACKGROUND: There is a critical need for improved prognostic discrimination in patients with renal cell carcinoma (RCC) given the increasing awareness that some patients may be managed with active surveillance, while others with higher-risk disease might benefit from adjuvant therapy following surgery.
OBJECTIVE: To determine whether a multigene proliferation signature predicts long-term oncologic outcomes in surgically resected RCC. DESIGN, SETTING, AND PARTICIPANTS: The cell cycle proliferation (CCP) score was determined after radical nephrectomy for localized clear cell, papillary, or chromophobe RCC in 565 patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was disease-specific mortality (DSM), and disease recurrence was a secondary end point. Association with outcomes was evaluated by Cox proportional hazards survival analysis. The CCP score was compared with the Karakiewicz nomogram, and a composite (R-CCP) score was developed. RESULTS AND LIMITATIONS: A total of 68 patients (12%) recurred and 32 (6%) died of disease within 5 yr of nephrectomy. The CCP score was an independent predictor of recurrence (hazard ratio [HR] 1.50, 95% confidence interval [CI] 1.07-2.09) and DSM (HR 2.49, 95% CI 1.53-4.04) after adjusting for clinical variables using the baseline nomogram. The composite R-CCP score gave a Harrell's concordance index of 0.87 and stratified patients into low- (n=338) and high-risk (n=202) categories with 99% and 84% cancer-specific survival probabilities, respectively (p<0.001).
CONCLUSIONS: The CCP score is a significant, independent predictor of long-term oncologic outcomes in patients who have undergone nephrectomy for RCC. Combining the molecular classifier with baseline clinical variables allows for accurate, patient-specific risk assessment for use in guiding clinical management. PATIENT
SUMMARY: In this study, we sought to understand how well gene expression information from individual kidney tumors can predict cancer recurrence and death following surgical removal. We found that the combination of the gene expression test and clinical characteristics provides an accurate prognostic assessment to help inform clinical decisions.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Kidney cancer; Molecular classifier; Predictive models; Renal cell carcinoma

Mesh:

Year:  2017        PMID: 29249291     DOI: 10.1016/j.eururo.2017.12.002

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

Review 1.  Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management.

Authors:  Andrew W Silagy; Alejandro Sanchez; Brandon J Manley; Karim Bensalah; Axel Bex; Jose A Karam; Börje Ljungberg; Brian Shuch; A Ari Hakimi
Journal:  Eur Urol Focus       Date:  2019-04-28

Review 2.  Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Authors:  Nieves Martinez Chanza; Abhishek Tripathi; Lauren C Harshman
Journal:  Curr Treat Options Oncol       Date:  2019-05-03

3.  Genomic Heterogeneity and the Small Renal Mass.

Authors:  Daiki Ueno; Zuoquan Xie; Marta Boeke; Jamil Syed; Kevin A Nguyen; Patrick McGillivray; Adebowale Adeniran; Peter Humphrey; Garrett M Dancik; Yuval Kluger; Zongzhi Liu; Harriet Kluger; Brian Shuch
Journal:  Clin Cancer Res       Date:  2018-05-14       Impact factor: 12.531

Review 4.  Current Management of Small Renal Masses, Including Patient Selection, Renal Tumor Biopsy, Active Surveillance, and Thermal Ablation.

Authors:  Alejandro Sanchez; Adam S Feldman; A Ari Hakimi
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

5.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.

Authors:  Johannes C van der Mijn; Bashir Al Hussein Al Awamlh; Aleem Islam Khan; Lina Posada-Calderon; Clara Oromendia; Jonathan Fainberg; Mark Alshak; Rahmi Elahjji; Hudson Pierce; Benjamin Taylor; Lorraine J Gudas; David M Nanus; Ana M Molina; Joseph Del Pizzo; Douglas S Scherr
Journal:  PLoS One       Date:  2019-12-09       Impact factor: 3.240

Review 6.  Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy.

Authors:  Kalle E Mattila; Paula Vainio; Panu M Jaakkola
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

7.  gga-microRNA-375 negatively regulates the cell cycle and proliferation by targeting Yes-associated protein 1 in DF-1 cells.

Authors:  Xinheng Zhang; Zhihong Liao; Yu Wu; Yiming Yan; Sheng Chen; Shaoli Lin; Feng Chen; Qingmei Xie
Journal:  Exp Ther Med       Date:  2020-05-04       Impact factor: 2.447

8.  Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients.

Authors:  Ying Xiong; Zewei Wang; Quan Zhou; Han Zeng; Hongyu Zhang; Zhaopei Liu; Qiuren Huang; Jiajun Wang; Yuan Chang; Yu Xia; Yiwei Wang; Li Liu; Yu Zhu; Le Xu; Bo Dai; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

9.  Influence of gene expression on survival of clear cell renal cell carcinoma.

Authors:  Anders Berglund; Ernest K Amankwah; Young-Chul Kim; Philippe E Spiess; Wade J Sexton; Brandon Manley; Hyun Y Park; Liang Wang; Jad Chahoud; Ratna Chakrabarti; Chang D Yeo; Hung N Luu; Giuliano D Pietro; Alexander Parker; Jong Y Park
Journal:  Cancer Med       Date:  2020-09-28       Impact factor: 4.452

10.  PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma.

Authors:  Jinfeng Gan; Hao Zhang
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.